← Back to Search

Prostaglandin Analog

Bimatoprost Solutions for Glaucoma

Phase 1
Recruiting
Research Sponsored by Amneal Pharmaceuticals, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Baseline (Day 0/hour 0) IOP ≥22 mm Hg and <28 mm Hg in each eye, with difference between the IOP in left and right eyes not being more than 5 mm Hg
Male or females aged ≥18 years
Must not have
Female who are pregnant, lactating or planning a pregnancy
Current or history of severe hepatic or renal impairment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 00.00 hour, 04.00 hours (4 hours ±1 hour after 00.00 hour), and 08.00 hours (8 hours ±1 hour after 00.00 hour) at day 14 (week 2) (± 4 days) and day 42 (week 6) (± 4 days) visits
Awards & highlights
No Placebo-Only Group

Summary

This trial compares two different treatments to see if they are equivalent, using a method where neither the patients nor the researchers know which treatment is being given.

Who is the study for?
This trial is for people with chronic open-angle glaucoma or ocular hypertension in both eyes. Specific eligibility criteria are not provided, but typically participants would need to meet certain health standards and not be on conflicting medications.
What is being tested?
The study is testing the effectiveness of a Bimatoprost Ophthalmic Solution against LUMIGAN®, which is an established treatment. Participants will be randomly assigned to one of two groups, receiving either the test solution or LUMIGAN® without knowing which one they're getting.
What are the potential side effects?
While specific side effects are not listed here, bimatoprost solutions like LUMIGAN® can cause eye redness, growth of eyelashes, itchy eyes, dryness, darkening of the iris and skin around the eyes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My initial eye pressure was between 22 and 28 mm Hg, with less than a 5 mm Hg difference between my eyes.
Select...
I am 18 years old or older.
Select...
I have chronic open-angle glaucoma or high eye pressure in both eyes.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not pregnant, breastfeeding, or planning to become pregnant.
Select...
I have or had severe liver or kidney problems.
Select...
I have had a corneal transplant.
Select...
My eye pressure was high and not controlled by bimatoprost alone.
Select...
I have a severe eye disease.
Select...
I do not have any uncontrolled illnesses.
Select...
I have a history of HBV, HCV, or HIV.
Select...
I have used an intraocular corticosteroid implant before.
Select...
I have eye conditions that could affect pressure readings.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~00.00 hour, 04.00 hours (4 hours ±1 hour after 00.00 hour), and 08.00 hours (8 hours ±1 hour after 00.00 hour) at day 14 (week 2) (± 4 days) and day 42 (week 6) (± 4 days) visits
This trial's timeline: 3 weeks for screening, Varies for treatment, and 00.00 hour, 04.00 hours (4 hours ±1 hour after 00.00 hour), and 08.00 hours (8 hours ±1 hour after 00.00 hour) at day 14 (week 2) (± 4 days) and day 42 (week 6) (± 4 days) visits for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Primary Endpoint
Secondary study objectives
Secondary Endpoint

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Bimatoprost Ophthalmic Solution, 0.01%Experimental Treatment1 Intervention
Test Product: Bimatoprost Ophthalmic Solution, 0.01%
Group II: LUMIGAN® (bimatoprost ophthalmic solution) 0.01%Active Control1 Intervention
Reference Product: LUMIGAN® (bimatoprost ophthalmic solution) 0.01%

Find a Location

Who is running the clinical trial?

CBCC Global Inc.UNKNOWN
Amneal Pharmaceuticals, LLCLead Sponsor
12 Previous Clinical Trials
28,265 Total Patients Enrolled
1 Trials studying Ocular Hypertension
168 Patients Enrolled for Ocular Hypertension
Amneal EU, LimitedUNKNOWN
~65 spots leftby Mar 2025